The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses

Abstract The capacity of an adjuvant to reduce the amount of antigen required in vaccines would be beneficial in a variety of settings, including situations where antigen is difficult or expensive to manufacture, or in situations where demand exceeds production capacity, such as pandemic influenza. The ability to reduce antigen dose would also be a significant advantage in combination vaccines, and vaccines that by necessity must contain multiple antigens to accommodate variability between strains or genotypes. ISCOMATRIX™ adjuvant was compared to aluminium hydroxide adjuvant (Al(OH3 )) for induction of antibody responses and dose sparing of a recombinant HIV gp120 vaccine. Neutralising antibody responses were significantly greater, at the same protein dose, when the gp120 protein was formulated with ISCOMATRIX™ adjuvant compared to Al(OH3 ). Moreover, strong responses were achieved with up to 100-fold lower doses of gp120 using ISCOMATRIX™ adjuvant. Therefore, ISCOMATRIX™ adjuvant has the potential to substantially reduce the dose of antigen required in human vaccines, without compromising the immune response.